Unknown

Dataset Information

Is chemodenervation with incobotulinumtoxinA an alternative to invasive chronic anal fissure treatments?


ABSTRACT:

Background

Botulinum toxin type A is currently strongly recommended for the treatment of anal fissures (AFs). However, there is still no consensus on dosage or injection technique. This study provides further efficacy and safety evidence in a 2-year follow-up.

Method

Prospective, open-label, single-arm, single-center study carried out in adult patients with AFs non-responsive to previous treatments. Patients were treated with incobotulinumtoxinA (incoBoNT/A) injected in both laterals and posterior intersphincteric groove. Healing rate at 2 years was the primary endpoint. Secondary endpoints included internal anal sphincter pressures, incontinence, and safety.

Results

A total of 49 patients were treated with a mean incoBoNT/A dose of 40.5 U (spread across three locatio

SUBMITTER: Calderon T 

PROVIDER: S-EPMC11440925 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature